Advanced company searchLink opens in new window

INTERCEPT PHARMA EUROPE LTD.

Company number 09224395

Filter by category

Filter by category


Confirmation statement filters

Company Results (links open in a new window)
Date (document was filed at Companies House) Type Description (of the document filed at Companies House) View / Download (PDF file, link opens in new window)
30 Apr 2024 TM01 Termination of appointment of Graham Charles Higson as a director on 27 April 2024
17 Feb 2024 AA Full accounts made up to 31 December 2022
27 Nov 2023 TM01 Termination of appointment of Stephanie Rose Kenyon as a director on 23 November 2023
22 Nov 2023 TM01 Termination of appointment of David Ford as a director on 21 November 2023
10 Nov 2023 RESOLUTIONS Resolutions
  • RES10 ‐ Resolution of allotment of securities
06 Nov 2023 SH19 Statement of capital on 6 November 2023
  • GBP 1
06 Nov 2023 CAP-SS Solvency Statement dated 03/11/23
06 Nov 2023 SH20 Statement by Directors
06 Nov 2023 RESOLUTIONS Resolutions
  • RES06 ‐ Resolution of reduction in issued share capital
  • RES13 ‐ Cancellation of share premium account/amount credited to a reserve 03/11/2023
05 Nov 2023 SH01 Statement of capital following an allotment of shares on 3 November 2023
  • GBP 76,835,864
30 Oct 2023 CH01 Director's details changed for Rocco Venezia on 30 October 2023
09 Oct 2023 CS01 Confirmation statement made on 30 September 2023 with updates
03 Mar 2023 AA Full accounts made up to 31 December 2021
24 Jan 2023 AP01 Appointment of Mr Graham Higson as a director on 24 January 2023
24 Jan 2023 AP01 Appointment of Ms Kathleen Munster as a director on 24 January 2023
24 Jan 2023 AP01 Appointment of Ms Stephanie Rose Kenyon as a director on 24 January 2023
24 Jan 2023 AP01 Appointment of Mr David Ford as a director on 24 January 2023
24 Jan 2023 TM01 Termination of appointment of Michael Gemellaro as a director on 24 January 2023
24 Jan 2023 TM01 Termination of appointment of Linda Richardson as a director on 24 January 2023
23 Dec 2022 SH01 Statement of capital following an allotment of shares on 22 December 2022
  • GBP 288
04 Oct 2022 CS01 Confirmation statement made on 30 September 2022 with updates
26 Jul 2022 CH01 Director's details changed for Mr Michael Gemellaro on 26 July 2022
26 Jul 2022 CH01 Director's details changed for Linda Richardson on 26 July 2022
26 Jul 2022 PSC05 Change of details for Intercept Pharmaceuticals, Inc. as a person with significant control on 26 July 2022
26 Jul 2022 CH01 Director's details changed for Rocco Venezia on 26 July 2022